Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| CVKD | PRESS-RELEASE | bearish | 5/10 | Cadrenal Therapeutics announced a $3M private placement with H.C. Wainwright, selling 960,000 shares and warrants that c | Jun 30, 2026 |
| CRNX | PRESS-RELEASE | neutral | 1/10 | Crinetics Pharmaceuticals, Inc. announced it will report its Q2 2026 results on August 4, 2026. | Jun 30, 2026 |
| CELZ | PRESS-RELEASE | bearish | 7/10 | Creative Medical Technology Holdings raised approximately $4.5 million by inducing immediate exercise of existing warran | Jun 30, 2026 |
| ASND | PRESS-RELEASE | bullish | 5/10 | Ascendis Pharma reported Week 104 data from the pivotal ApproaCH Trial showing continued improvement in lower extremity | Jun 30, 2026 |
| CADL | PRESS-RELEASE | bullish | 7/10 | Candel Therapeutics announced the initiation of a global pivotal Phase 3 AURORA trial (NCT07660094) evaluating aglatimag | Jun 30, 2026 |
| PYXS | PRESS-RELEASE | mixed | 6/10 | Pyxis Oncology announced a $50M private placement (plus up to $64M from warrants) led by BVF Partners, extending cash ru | Jun 30, 2026 |
| IFRX | PRESS-RELEASE | bullish | 7/10 | InflaRx announced it is assessing a broader development and registrational strategy for ANCA-associated vasculitis (AAV) | Jun 30, 2026 |
| PSTV | PRESS-RELEASE | neutral | 4/10 | Plus Therapeutics announced a corporate rebranding to Cerenome and a Nasdaq ticker change to CNSY effective August 3, 20 | Jun 30, 2026 |
| ACIU | PRESS-RELEASE | mixed | 4/10 | AC Immune reported interim 12-month data from the Phase 1b/2 ABATE trial of ACI-24 in prodromal Alzheimer's disease. The | Jun 30, 2026 |
| HCM | PRESS-RELEASE | neutral | 1/10 | HUTCHMED (China) Limited announced it will report its half-year 2026 results on July 30, 2026. | Jun 30, 2026 |
| NVCT | PRESS-RELEASE | bearish | 6/10 | Nuvectis Pharma priced an underwritten public offering of 5,000,000 shares at $20.00/share for gross proceeds of $100 mi | Jun 29, 2026 |
| ARQT | PRESS-RELEASE | bullish | 7/10 | Arcutis Biotherapeutics received FDA approval to expand ZORYVE cream 0.3% for plaque psoriasis to children as young as 2 | Jun 29, 2026 |
| GANX | PRESS-RELEASE | bullish | 5/10 | Gain Therapeutics announced FDA authorization of its IND application for GT-02287, allowing Phase 2 clinical development | Jun 29, 2026 |
| ABVX | PRESS-RELEASE | bullish | 7/10 | Abivax reported positive topline results from ABTECT Maintenance Part 2 for obefazimod in refractory ulcerative colitis, | Jun 29, 2026 |
| AKTX | PRESS-RELEASE | bullish | 7/10 | Akari Therapeutics completed its previously announced PIPE financing, consolidating remaining tranches into a single clo | Jun 29, 2026 |
| REPL | PRESS-RELEASE | bullish | 7/10 | Replimune reported a fiscal Q4 2026 EPS miss of -$0.77 vs -$0.72 consensus, a -6.9% surprise, with no revenue. The highl | Jun 29, 2026 |
| AGIO | PRESS-RELEASE | neutral | 1/10 | Agios Pharmaceuticals, Inc. announced it will host a conference call on July 30 to discuss its Q2 2026 results. | Jun 29, 2026 |
| DNTH | PRESS-RELEASE | bullish | 5/10 | Dianthus Therapeutics initiated the Phase 3 EMERGE trial of claseprubart in generalized Myasthenia Gravis, building on p | Jun 29, 2026 |
| ZYME | PRESS-RELEASE | bullish | 7/10 | Zymeworks Inc. (ZYME) announced an agreement to acquire Theravance Biopharma (TBPH) for $17.00 per share, or approximate | Jun 29, 2026 |
| AMRX | PRESS-RELEASE | bullish | 5/10 | Zambon and Amneal announced that the CHMP adopted a positive opinion recommending EU marketing authorization for Hopledo | Jun 29, 2026 |
| BBIO | PRESS-RELEASE | bullish | 8/10 | BridgeBio announced positive Phase 3 PROPEL 3 results for oral infigratinib in achondroplasia, published in NEJM and pre | Jun 28, 2026 |
| NEUP | PRESS-RELEASE | bullish | 6/10 | Neuphoria Therapeutics confirms it is in preliminary discussions with UK-based Scancell Holdings regarding a potential a | Jun 26, 2026 |
| MNPR | PRESS-RELEASE | bullish | 7/10 | Monopar Therapeutics presented new positive analyses from the Phase 3 FoCus trial of ALXN1840 in Wilson disease at EAN 2 | Jun 26, 2026 |
| TSHA | PRESS-RELEASE | bearish | 7/10 | Taysha Gene Therapies announced the pricing of a $200M underwritten public offering of 32.5M shares at $6.00/share, plus | Jun 24, 2026 |
| HCM | PRESS-RELEASE | bullish | 7/10 | HUTCHMED announced positive pivotal Phase II results for fanregratinib in FGFR2-fusion/rearrangement intrahepatic cholan | Jun 24, 2026 |
| VRXA | PRESS-RELEASE | neutral | 2/10 | VERAXA Biotech announced the expansion of its R&D facility in Heidelberg, Germany under a previously signed long-term le | Jun 24, 2026 |
| ABSI | PRESS-RELEASE | bullish | 7/10 | Absci Corporation announced a $100 million underwritten offering of 13,495,277 shares at $7.41 per share, with participa | Jun 24, 2026 |
| ABSI | PRESS-RELEASE | bullish | 7/10 | Absci reported positive interim Phase 1 data for ABS-201, an anti-prolactin receptor antibody for androgenetic alopecia | Jun 24, 2026 |
| LODE | PRESS-RELEASE | neutral | 3/10 | Comstock Inc. announced that its subsidiary Comstock Metals will open a solar panel recycling facility in Cambridge, Ohi | Jun 24, 2026 |
| MLTX | PRESS-RELEASE | bearish | 6/10 | MoonLake Immunotherapeutics priced a $200M underwritten public offering of 9M Class A ordinary shares at $20.00 per shar | Jun 23, 2026 |